ARTICLE | Clinical News
Chimerix falls after brincidofovir update
February 23, 2016 2:39 AM UTC
Chimerix Inc. (NASDAQ:CMRX) fell $3.08 (40%) to $4.55 on Monday after reporting detailed data over the weekend from the Phase III SUPPRESS trial of brincidofovir ( CMX001) to prevent cytomegalovirus (CMV) infections and discontinuing two other trials of the compound.
In December, brincidofovir missed the primary endpoint in SUPPRESS, which evaluated whether the compound could prevent clinically significant CMV infections through week 24 in hematopoietic stem cell transplant (HSCT) recipients (see BioCentury Extra, Dec. 28, 2015). ...